January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
2 citations
,
January 2020 in “Einstein (São Paulo)” Topical tofacitinib shows promise as a future treatment for alopecia areata.
37 citations
,
September 2017 in “Reumatología Clínica” Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.
1 citations
,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
9 citations
,
July 2002 in “Journal of the European Academy of Dermatology and Venereology” The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
April 2021 in “Research Square (Research Square)” The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
February 2016 in “Annals of the Rheumatic Diseases” All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
August 2025 in “Saudi Pharmaceutical Journal” The ointment effectively treats neurodermatitis and chronic eczema without causing skin irritation.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.